- Apexigen Inc APGN announced the Presentation of new data from a phase 2 study evaluating sotigalimab (Sotiga) in combination with neoadjuvant chemoradiotherapy in resectable esophageal and gastroesophageal junction (GEJ) cancer.
- Sotiga in combination with neoadjuvant chemoradiotherapy for esophageal/GEJ cancer was generally safe and well tolerated.
- Most patients experienced Grade 1-2 adverse events (AEs).
- There were no patient discontinuations due to Sotiga and no deaths related to Sotiga/neoadjuvant chemoradiotherapy.
- Encouraging pathologic complete response (pCR) rates have been observed in both adenocarcinoma (AC) and squamous cell carcinoma (SCC) patients.
- Of the 29 evaluable patients, 11 (38%) patients had pCR and 19 (66%) patients had mPR (significant pathologic response), with less than 10% residual tumor remaining after treatment.
- The pCR rate was 41.2% in patients (n=17) who received four doses of Sotiga versus 33.3% in patients (n=12) who received three doses.
- R0 resection was achieved in 86% (25/29) of patients and disease progression was only 7%.
- Price promotion: APGN shares are down 8.02% to $7.00 during the premarket session last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
